iECURE, inc.’s Post

🌟 Exciting news for Ontario's biotech scene! OmniaBio has officially opened 𝘾𝙖𝙣𝙖𝙙𝙖’𝙨 𝙡𝙖𝙧𝙜𝙚𝙨𝙩 𝙘𝙚𝙡𝙡 𝙖𝙣𝙙 𝙜𝙚𝙣𝙚 𝙩𝙝𝙚𝙧𝙖𝙥𝙮 (𝘾𝙂𝙏) biomanufacturing facility in #Hamilton! 🧬💉 This game-changing project, supported by Invest Ontario, is set to revolutionize healthcare, creating 250 skilled jobs and bringing life-saving therapies to the global market. 🌍 Watch the video to discover more about OmniaBio’s groundbreaking work and how Invest Ontario can help 𝗴𝗿𝗼𝘄 𝘆𝗼𝘂𝗿 𝗯𝘂𝘀𝗶𝗻𝗲𝘀𝘀. 🎥👇

We are pleased to share that Labiotech.eu published an article about the companies that are transforming the biotech industry in Italy, among which two of the seven mentioned are part of our portfolio companies, namely Alia Therapeutics and Sibylla Biotech.   Alia Therapeutics develops innovative treatments for incurable genetic diseases based on gene editing technology, while Sibylla Biotech has a proprietary technological platform able to design protein degraders for targets that are currently non druggable. The article underlines some challenges that Italian biotech companies have to face, in particular the lower availability of capital compared to other eco-systems. We believe that #Indaco with our Indaco Bio Fund and few other Italian and international investors are currently contributing to fill such gap investing a growing amount of capital in Italian companies that have groundbreaking ideas, creating the basis for a “Biotech Renaissance” of Italy. Read the full article here: https://lnkd.in/dzmtEBbn   #VentureCapital #Biotech

LucidQuest Strategic Insights (lqventures.com) >>> Gene&Cell Therapy >> Metagenomi science chief departs, just a few months after IPO: The chief scientific officer at gene editing company Metagenomi is out, the company confirmed to Endpoints News. “As of yesterday, I have parted ways with Metagenomi by mutual agreement,” CSO Luis Borges posted to LinkedIn last week. He had joined the company last year after serving in the same role at cell therapy maker Century Therapeutics. His exit comes just five months after the Emeryville, CA-based startup followed through with an initial public offering, a rare move for a preclinical biotech amid the public market weakness of the past few years. It priced the February IPO at $15 per share $MGX and trades at about $5 apiece today. “We came to a mutual separation with Luis Borges, and wish him all the best in future endeavors,” a Metagenomi spokesperson said by email. Also this week, another scientist at Metagenomi posted on LinkedIn that their “department in R&D was officially eliminated” and that they were looking for new roles elsewhere in the Bay Area. “We do not comment on prior employees’ LinkedIn posts, which may or may not be accurate,” the Metagenomi spokesperson said about that post. As of March 31, Metagenomi had 237 full-time employees, including 200 focused on R&D. With $327.4 million at the end of the first quarter, the company predicted in May it would have enough cash to support operations “into 2027.” Layoffs continue to impact employees across the biopharma industry. Gene therapy maker Spark Therapeutics is notifying employees of layoffs this week, Endpoints reported on Thursday, and large pharmaceutical corporations like Takeda, Sanofi, Pfizer and others are cutting jobs and shuttering sites as they prioritize their pipelines. Metagenomi also lost a key partnership with Moderna in May, in a move that Metagenomi described as “mutual.” The company still has partnerships with Ionis and Affini-T. Its pipeline includes projects across hemophilia A, cardiovascular disease, cystic fibrosis and various rare diseases, among other areas. Its ex vivo CAR-T programs are in the areas of immuno-oncology and autoimmune diseases, where cell therapies have recently become a fixture. #lucidquest #genetherapy #celltherapy

#CEBioForum2024 conference started today in Warsaw. This anual event gathers a majority of movers and shakers from the Polish and also Central European biotech field. Today's topics included, among others, the impact of cell and gene therapy on the market and patients , tips on how to enter the US market and proper preparation for clinical trials. Apart from that there were some interesting company'a presentations, such as from Indica Labs or SyVento BioTech. As always I had a pleasure to represent POLSERVICE Patent and Trademark Attorneys Office. It's fascinating to watch this sector grow and flourish! The motto for today: All you need is science...and...good IP protection! #IP #Biotech #patents #Polservice #Ryvu #BioForum

Gene&Cell Therapy >> Metagenomi science chief departs, just a few months after IPO: The chief scientific officer at gene editing company Metagenomi is out, the company confirmed to Endpoints News. “As of yesterday, I have parted ways with Metagenomi by mutual agreement,” CSO Luis Borges posted to LinkedIn last week. He had joined the company last year after serving in the same role at cell therapy maker Century Therapeutics. His exit comes just five months after the Emeryville, CA-based startup followed through with an initial public offering, a rare move for a preclinical biotech amid the public market weakness of the past few years. It priced the February IPO at $15 per share $MGX and trades at about $5 apiece today. “We came to a mutual separation with Luis Borges, and wish him all the best in future endeavors,” a Metagenomi spokesperson said by email. Also this week, another scientist at Metagenomi posted on LinkedIn that their “department in R&D was officially eliminated” and that they were looking for new roles elsewhere in the Bay Area. “We do not comment on prior employees’ LinkedIn posts, which may or may not be accurate,” the Metagenomi spokesperson said about that post. As of March 31, Metagenomi had 237 full-time employees, including 200 focused on R&D. With $327.4 million at the end of the first quarter, the company predicted in May it would have enough cash to support operations “into 2027.” Layoffs continue to impact employees across the biopharma industry. Gene therapy maker Spark Therapeutics is notifying employees of layoffs this week, Endpoints reported on Thursday, and large pharmaceutical corporations like Takeda, Sanofi, Pfizer and others are cutting jobs and shuttering sites as they prioritize their pipelines. Metagenomi also lost a key partnership with Moderna in May, in a move that Metagenomi described as “mutual.” The company still has partnerships with Ionis and Affini-T. Its pipeline includes projects across hemophilia A, cardiovascular disease, cystic fibrosis and various rare diseases, among other areas. Its ex vivo CAR-T programs are in the areas of immuno-oncology and autoimmune diseases, where cell therapies have recently become a fixture. #lucidquest #genetherapy #celltherapy

Gain insight into the latest innovations and trends in Biopharmaceuticals, Sustainable Food Production, and Process Analytical Technology (PAT). #biotechnology #analyticalinstruments #mettlertoledo #microsep

Ready to bring your scientific ideas to life? 🧪Our biotechnology lab solutions can help! Our analytical instruments are designed to help you achieve your research goals quickly and efficiently, whether you're exploring gene sequencing, drug discovery, or bioenergy. 🔬With our cutting-edge lab solutions, you can take your research to the next level. Check out our video to see our technology in action and learn how we can help you achieve your scientific breakthroughs. And if you want to dig deeper, check out our METTLER TOLEDO Laboratory Solutions guide for more information. Don't settle for less when it comes to your research. Partner with us and let's bring your ideas to life! #biotechnology #labsolutions #science #research #innovation #cuttingedge

Thanks to Adrian Keatinge-Clay and his lab at The University of Texas at Austin for sharing the challenges of high complexity, #longDNA PKS (polyketide synthases) gene cluster synthesis! The Keatinge-Clay lab joined ELEGEN's Early Access Program, where they ordered the de novo synthesis of a 14,713bp plasmid containing a complex PKS gene cluster. Elegen delivered, shaving off 1-2 wks of time and labor. “With Elegen’s ability to synthesize regions of high complexity, the Keatinge-Clay lab is able to move projects with difficult, complex sequences, including repetitive GC-rich regions, from the drawing board to the incubators in a matter of weeks.” Read the case study: https://bit.ly/3U5Ma1H #plasmidsynthesis #SyntheticDNA #synbio #DNA innovation #EnfiniaDNA

In 9 days, on June 14-15 (Fri-Sat), the SAPA-GP 2024 @Philly Cell and Gene Therapy Annual Conference will be held in KOP near Philly at the Sheraton Valley Forge Hotel. This is the third conference in three years and each year we drew up to 600 attendees, more than 10% of them were biotech founders, co-founders, CEOs, and C level executives. Philly possesses high quality and availability of infrastructure, large talent pool, and abundant biotech service providers. It's a fertile ground for biotech investors to grow their portfolio companies. This year our business track is putting strong emphasis in investment topics. I want to highlight the investment panel on June 14 (Fri) afternoon (2-3:30pm) presenting six biotech investors from NYC and Boston whose interests span from early investment to M/A and IPO. The topic is "Hidden Traps: What Makes Investors Walk Away From Your Pitch?"  It's a fantastic opportunity to have seasoned biotech investors to tell you what's not working and how to improve your fundraising pitch. To register for the conference, please go to https://lnkd.in/eVdfyxN3.  

Unleash the Potential of Your Research: Advanced Solutions for Biotech Labs 👩🔬 Our cutting-edge biotechnology lab solutions empower you to accelerate breakthroughs 💯. From gene sequencing to drug discovery 💊 and bioenergy research, our high-performance analytical instruments 👩🔬 are designed to streamline your workflow and maximize efficiency 😀 Are you ready to take your research to the next level? 🤔 #METTLERTOLEDO #Analytical #Laboratory #AdvancedSolutions #HighPerformance #Workflow